Showing 1791-1800 of 1861 results for "".
- STELARA Wins 2012 International Prix Galien Awardhttps://practicaldermatology.com/news/20121022-stelara_wins_2012_international_prix_galien_award/2459698/Janssen Biotech, Inc. announced that STELARA was named the 2012 International Prix Galien award winner in Lyon, France. The honor is acknowledgment of the technical, scientific, and clinical research skills necessary to develop innovative medicines and devices. The international Prix Galien Award is
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- ASDS: Study Shows that PCPs Favor Dermatologists for Cosmetic Procedureshttps://practicaldermatology.com/news/20121016-new_study_from_asds_shows_that_pcps_favor_dermatologists_for_cosmetic_procedures/2459705/Recent survey data presented at the recent ASDS Meeting in Atlanta and published in the October edition of Dermatologic Surgery finds that almost two-thirds of physicians chose dermatologists as the most qualified to perform cosmetic procedures for wrinkles and skin rejuvenation. Additionally, resul
- ADCS Clinics Acquires Additional Practicehttps://practicaldermatology.com/news/20121010-adcs_clinics_acquires_additional_practice/2459710/Less than a week after announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of Winter Park Dermatology. The practice is located in Wint
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- ADCS Acquires Additional Clinicshttps://practicaldermatology.com/news/20121008-adcs_acquires_additional_clinics/2459714/Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of the Center For Dermatology & Skin Surgery, Inc. (CDSS) and its seven clinics in West Central Florida. Headquartered in Tampa, FL, CDSS was founded by Steve
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Star Scientific's Rock Creek Pharmaceuticals, Inc. Launches New Producthttps://practicaldermatology.com/news/20120926-star_scientifics_rock_creek_pharmaceuticals_inc_launches_new_product/2459728/Star Scientific, Inc., through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc., announced the new Anatabloc face cream, which is available on the cosmetic portion of the Anatabloc website and in select dermatology practices. The pro
- Lucid, Inc. Now Named Caliber IDhttps://practicaldermatology.com/news/20120926-lucid_inc_now_named_caliber_id/2459729/Lucid, Inc. announced that it is now operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real tim
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),